The power of suggestion and anticipation can be just as potent as a drug it seems, especially when it comes to sex. Or at least that’s one of the conclusions that could be reached in the aftermath of phase 3 clinical trials testing the efficacy of LibiGel, which is designed to treat sexual dysfunction in […]
A gel developed by Antares (AMEX:AIS) and licensed to BioSante Pharmaceuticals (NASDAQ:BPAX) to treat female sexual dysfunction failed two phase 3 clinical trials testing efficacy, according to a statement from BioSante. Initial analysis of the data from the trials showed that the tests “did not meet the co-primary or secondary endpoints,” the statement said. LibiGel […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Highlights of the important and the interesting from the world of healthcare: FDA panel to consider pulling Avandia. An expert panel of the U.S. Food and Drug Administration is planning a mid-July meeting to consider whether GlaxoSmithKline’s (NYSE: GSK) diabetes drug Avandia should be pulled from the market. Dr. Steven Nissen of the Cleveland Clinic […]
Shares of BioSante Pharmaceuticals rose 10 percent after the company reported positive results from a clinical study of a leukemia vaccine. The Phase 2 trial showed that BioSante’s GVAX vaccine “may be able to reduce or eliminate” the last remaining cancer cells in patients who are suffering from chronic myeloid leukemia and taking the drug […]
BioSante Pharmaceuticals Inc. has received funding commitments totaling $18 million from two institutional investors. The company plans to use the proceeds to continue funding a Phase 3 clinical trial of LibiGel, a drug that treats under-active sexual desire in menopausal women. BioSante says it plans to seek approval from the U.S. Food and Drug Administration […]
BioSante finalized the sale of approximately 6 million shares -- with warrants to purchase 2.4 million more shares -- to three institutional investors. The cash infusion will fund a Phase III study of LibiGel, which treats low sexual desire in women.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Illinois' BioSante paid $38 million in stock for Cell Genesys and an ownership stake in a former subsidiary. In exchange, it gains fresh money to get its LibiGel product through Phase III clinical development under a U.S. Food and Drug Administration Special Protocol Assessment.